Phase 2 N=15 A Study of CIN-107 in Adults With Primary Aldosteronism
Primary Aldosteronism · Hyperaldosteronism
Primary: Number of Treatment Emergent Adverse Events — 27; 34; 101 Number of events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 A Study of NIDO-361 in Patients With SBMA
Spinal and Bulbar Muscular Atrophy · Kennedy's Disease
Primary: Analysis of Thigh and Total Lean Muscle Volume (LMV) [A+B+C] — 4.1402; 3.8580; -0.0871; -0.1042 cm³
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=141 Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) — 25.8; 25.8; 24.8; 12.8 score on a scale
Phase 2 N=210 A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Incidence and Grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 130; 43; 25; 12 participants
Phase 2 N=12 Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
Soft-tissue Sarcoma
Primary: Count of Patients With Dose Limiting Toxicity — 0 Participants
Phase 2 N=179 A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
Venous Thromboembolism
Primary: Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) — 7.1; 17.2 percentage of participants
Phase 2 N=100 Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Primary: Disease Free Survival (DSF) Time- 2 Year Estimate — 48; 57 days
Phase 2 N=30 Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Multiple Myeloma (MM)
Primary: Overall Response Rate — 30; 0 Participants
Phase 2 N=30 Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
Pediatric Cancer
Primary: Percentage of Pediatric Patients Age 3-7 Who Require Daily General Anesthesia for All Treatments — 88; 12 percentage of participants
Phase 2 N=24 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
Gram-negative Bacterial Infections · Bloodstream Infections (BSI) · Complicated Intra-abdominal Infection (cIAI)
Primary: Single-Dose Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 1; 3; 1 Participants
Phase 2 N=10 Sintilimab in Cancer of Unknown Primary
Cancer of Unknown Primary Site
Primary: Confirmed Objective Response Rate (cORR) by RECISTv1.1 — 40 percentage of participants
Phase 2 N=30 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
Phase 2 N=3 A Study of ELX-02 in Patients With Alport Syndrome
Alport Syndrome
Primary: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily — 3 Participants
Phase 2 N=353 Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
Primary: Percent Change From Baseline at Week 24 in Fasting TG — -1.7; -51.5; -57.7; -64.1 percentage change — p=<0.0001